JPMorgan's increased passive stake to 5.2% suggests growing institutional confidence, but the passive filing designation limits near-term catalyst potential. Monitor for any conversion to a 13D filing, which would signal activist intent.
Price Chart
Executive Summary
JPMorgan Chase & Co. filed an amended Schedule 13G disclosing a 5.2% passive stake in Neurocrine Biosciences as of September 30, 2026, up from its prior filing. The filing confirms JPMorgan remains a passive investor with no activist intent, and the increased stake signals growing institutional conviction.
Key Financial Metrics
Key Facts
- JPMorgan Chase & Co. reported beneficial ownership of 5,300,390 shares of Neurocrine Biosciences common stock, representing 5.2% of shares outstanding as of September 30, 2026.
- The filing is an amendment to a prior Schedule 13G, indicating a passive investment intent under Rule 13d-1(b).
- JPMorgan's prior 13G/A filed July 27, 2026, did not include a stake percentage in the available document text, so the direction of change cannot be quantified from the provided documents.
Financial Impact
JPMorgan holds a 5.2% passive stake in Neurocrine Biosciences; no transaction values or cost basis disclosed.
Risk Factors
- JPMorgan could reduce its stake in future periods, which would be a negative signal.
- Passive 13G status means no activist pressure; the filing provides no direct catalyst for stock movement.
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| SC 13G/A Filing (Primary) | 0000019617-26-000371 |
| Document: 0000019617-26-000371-index.html | 0000019617-26-000371 |
| Document: 0000019617-26-000371.txt | 0000019617-26-000371 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | Institutional Cluster | $147.19 | awaiting T+60 | — | $146.00 (−0.81%) |
Oct 15, 2026 12d ago | SC 13G/A | $136.95 | awaiting T+60 | — | $146.00 (+6.61%) |
Oct 15, 2026 12d ago | Institutional Cluster | $136.95 | awaiting T+60 | — | $146.00 (+6.61%) |
Oct 7, 2026 20d ago | 3 | $141.25 | awaiting T+60 | — | $146.00 (+3.36%) |
Sep 15, 2026 6w ago | Insider Cluster | $149.50 | awaiting T+60 | — | $146.00 (−2.34%) |
Jul 13, 2026 15w ago | Insider Cluster | $172.04 $143.47 | ▼ −16.61% | ▼ −19.98% | $146.00 (−15.14%) |
Jul 9, 2026 15w ago | Press Release | $177.11 $144.21 | ▼ −18.58% | ▼ −21.21% | $146.00 (−17.57%) |
Jun 9, 2026 20w ago | Insider Cluster | $160.86 $158.35 | ▼ −1.56% | ▼ −8.14% | $146.00 (−9.24%) |
Jun 8, 2026 20w ago | Insider Cluster | $165.24 $157.79 | ▼ −4.51% | ▼ −8.32% | $146.00 (−11.64%) |
Jun 8, 2026 20w ago | Insider Cluster | $165.24 $157.79 | ▼ −4.51% | ▼ −8.32% | $146.00 (−11.64%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers